Table 2.

Actionable or prognostic genomic alterations in 10 FFPE tumor samples

SAMPLE	TUMOR TYPE	MEAN TARGET COVERAGE	Actionable in Principle		Prognostic / Diagnostic
SAMPLE	TUMOR TYPE	MEAN TARGET COVERAGE	Tier 1	Tier 2	Prognostic / Diagnostic
FFPE 1	Colon	457	KRAS (Q61H)^b	KRAS (Q61H)^a
FFPE 2	Colon	353	KRAS (G13C)^a	KRAS (G13C)^a
FFPE 3	Colon	498	KRAS (G13C)^a PIK3CA (H1047R)^b	KRAS (G13C)^a PIK3CA (H1047R)^a	MSH2 (R680*)^a
FFPE 4	Colon	300		BRAF (D594G)^d TSC1 (E258*)^c
FFPE 5	Breast	472	CCND1 amp^b FGFR1 amp^d	CCND1 amp^d FGFR1 amp^a	CCND1 amp^b
FFPE 6	Breast	532		BRCA1 (2-bp del)^a	BRCA1 (2-bp del)^a
FFPE 7	Colon	250	KRAS (G13D)^a PIK3CA (E545K)^b	KRAS (G13D)^a PIK3CA (E545K)^a
FFPE 8	Breast	537	PIK3CA (H1047R)^b	PIK3CA (H1047R)^a
FFPE 9	Colon	116			SMAD2 (S306*)^b
FFPE 10	Colon	410	KRAS (Q61H)^b	KRAS (Q61H)^a

clinically validated and approved alteration (for Tier 1 or Prognostic/Diagnostic) or specifically targeted alteration (for Tier 2) [shown in bold]

limited clinical evidence

clinical evidence in a different tumor type only

pre-clinical evidence only

Abbreviations: amp = amplification, del = deletion